contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


expres2ion-biotechnologies-expres2ion-to-present-in-upcoming-investor-and-scientific-events-3

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ExpreS2ion är ett bioteknikbolag fokuserat på utveckling av vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner ämnade att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.

ExpreS2ion Biotech Holding

Hørsholm, Denmark, 9 January 2025 - ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") is pleased to announce its participation in two key upcoming events...

<div class="abstract">Hørsholm, Denmark, 9 January 2025 - ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") is pleased to announce its participation in two key upcoming events: PepTalk - the Annual Protein Science and Production Week in San Diego, USA, and an Institutional Investor Seminar hosted by HC Andersen Capital in Copenhagen, Denmark.</div>These events represent important opportunities to showcase ExpreS2ion's innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the <a style="color:#52ab01; text-decoration:underline" href="https://expres2ionbio.com/media/events/">Company's website</a> and via the links below. To arrange a meeting at either event, please contact us at <a style="color:#52ab01; text-decoration:underline" href="mailto:info@expreS2ionbio.com">info@expreS2ionbio.com</a>.13-16 January 2025 | PepTalk - Protein Science and Production Week San Diego, California, USA PepTalk is a leading conference focused on advancing biotherapeutic discovery and development. On 16 January at 11:30 AM PST, ExpreS2ion's VP of R&amp;D and Technology, Max Søegaard, will present a talk titled "Advancements in VLP Technology: From Pandemic Countermeasures to Broad-Spectrum Applications in Vaccine Development." Additional details are available on the &nbsp;<a style="color:#52ab01; text-decoration:underline" href="https://www.chi-peptalk.com/">Peptalk website</a>.16 January 2025 | Institutional Investor Seminar Copenhagen, Denmark ExpreS2ion's CEO, Bent Frandsen, will present at an Institutional Investor Seminar hosted by HC Andersen Capital. The presentation will focus on ES2B-C001, ExpreS2ion's novel therapeutic breast cancer vaccine, which recently received Clinical Trial Application (CTA) approval from Austrian regulatory authorities for a Phase I clinical trial. Nordic institutional investors interested in attending are encouraged to contact <a style="color:#52ab01; text-decoration:underline" href="https://hcandersencapital.dk/">HC Andersen Capital</a> for participation details.Certified Adviser Svensk Kapitalmarknadsgranskning AB<div></div>

ExpreS2ion Biotechnologies: ExpreS2ion to Present in Upcoming Investor and Scientific Events

Bryter ekonomiska myter: Tysklands industri är ett minne blott

Federal Reserves räntebeslut: Bråkmakarna i farten

Måste man arbeta långa dagar? Ekonomen funderar

Bryter ekonomiska myter: Datacenterinvesteringar leder alltid till bättre AI

Uppgångsvecka bakom oss, USA:s sysselsättningsrecession syns fortfarande inte i siffrorna